Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Shri N. Giri"'
Publikováno v:
Pharmacology & Pharmacy. :238-247
Tumor necrosis factor-alpha (TNF-α) is a potent inflammatory cytokine and its exaggerated production has been implicated in acute, chronic and autoimmune inflammatory diseases. Proteinaceous and non-proteinaceous anti-TNF-α agents have been develop
Autor:
Ken J. Grattendick, Amy E Poulin Braim, Melinda H. MacDonald, M. L. Bruss, Solomon B. Margolin, Shri N. Giri
Publikováno v:
American Journal of Veterinary Research. 70:1031-1042
Objective—To characterize effects of IV administration of pirfenidone on clinical, biochemical, and hematologic variables and circulating tumor necrosis factor (TNF)-α concentrations in horses after infusion of a low dose of endotoxin. Animals—1
Autor:
Shri N. Giri, Scott D Stanley, Jill K Giri, Melinda H. MacDonald, Amy E Poulin Braim, M. L. Bruss
Publikováno v:
American Journal of Veterinary Research. 69:952-960
Objective—To characterize the plasma pharmacokinetics and clinical effects of pirfenidone administered IV in healthy horses. Animals—6 adult horses. Procedures—A 15 mg/kg dose of pirfenidone was administered IV over 5 minutes. Physical variable
Autor:
Kendra C. Decile, Shri N. Giri, Edward S. Schelegle, Kent E. Pinkerton, Jim K. Mansoor, Jennifer M. Bratt, William F. Walby, Harinder Grewal, Solomon B. Margolin
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 20:660-668
Pirfenidone was administered to sensitized Brown Norway rats prior to a series of ovalbumin challenges. Airway hyperresponsiveness, inflammatory cell infiltration, mucin and collagen content, and the degree of epithelium and smooth muscle staining fo
Publikováno v:
Multiple Sclerosis Journal. 11:149-158
Currently, there are no approved treatments for secondary progressive multiple sclerosis (MS) that stabilize or reverse the neurological disabilities associated with this disease. Oral pirfenidone was found to stabilize and overcome the disabilities
Publikováno v:
Biochemical Pharmacology. 64:517-525
Renal fibrosis is a complication of kidney injury and can contribute to organ failure. Currently, there are no drugs for the treatment of renal fibrosis. Pirfenidone (PD) has been proven to have antifibrotic effects in animal models of fibrosis. We t
Publikováno v:
Experimental Lung Research. 28:405-417
Transforming growth factor-beta (TGF-beta) plays a pivotal role in an exaggerated synthesis and accumulation of collagen in fibrotic disorders of many organs. We have previously demonstrated that repeated intratracheal (IT) instillation of TGF-beta s
Autor:
Solomon B. Margolin, Jozsef Lango, Alan R. Buckpitt, Dexter Morin, Yan Xie, Qingjian Wang, Shri N. Giri
Publikováno v:
Biopharmaceutics & Drug Disposition. 23:203-211
The present study describes the pharmacokinetics and metabolism of pirfenidone (PD), a compound which has been shown to have significant antifibrotic effects in rodent models of pulmonary and cardiac fibrosis. Despite the fact that this compound is c
Publikováno v:
Research communications in molecular pathology and pharmacology.
Septic shock results from a systemic host response to infection, in particular, and is associated with multiorgan dysfunction (MOD). Effective preventive measures against organ failure are essential as it is the cumulative burden of MOD that invariab
Publikováno v:
Archives of Biochemistry and Biophysics. 379:109-118
The ryanodine-sensitive calcium channels, also called ryanodine receptors, are intracellular Ca(2+)-release channels that have been shown to bind the neutral plant alkaloid ryanodine with nanomolar affinity. The activity of the skeletal muscle (RyR1)